The American Psychiatric Association (APA) has updated its Privacy Policy and Terms of Use, including with new information specifically addressed to individuals in the European Economic Area. As described in the Privacy Policy and Terms of Use, this website utilizes cookies, including for the purpose of offering an optimal online experience and services tailored to your preferences.

Please read the entire Privacy Policy and Terms of Use. By closing this message, browsing this website, continuing the navigation, or otherwise continuing to use the APA's websites, you confirm that you understand and accept the terms of the Privacy Policy and Terms of Use, including the utilization of cookies.

×
Communications and UpdatesFull Access

Impact of Hypertension and Body Mass Index on Quality of Life in Schizophrenia

To the Editor: We were pleased to read the article by Joseph I. Friedman, M.D., and colleagues in the October 2010 issue of the Journal (1). The article highlights the negative impact of individual cardiovascular risk factors, particularly hypertension, on memory performance in patients with schizophrenia, and suggests that proper treatment of these risk factors may improve cognitive outcomes in these patients.

Pronounced memory deficits have been linked to low quality of life in patients with schizophrenia (2). In recent years, the importance of predictors of quality of life on treatment outcomes among these patients is being recognized (3). We analyzed quality of life among patients with schizophrenia who had hypertension and a body mass index (BMI) >25 as reported in the National Epidemiologic Survey on Alcohol and Related Conditions (N=43,093), a large representative U.S. survey. This survey assessed substance use and mental and physical disorders, including history of schizophrenia, as well as self-reported hypertension and a high BMI in the past 12 months.

We measured quality of life using the 12-item Short-Form Health Survey, a norm-based general health scale, for eight subgroups: participants with schizophrenia with and without hypertension (N=134 and N=252, respectively) or with and without a BMI >25 (N=251 and N=125, respectively) and healthy comparison subjects (participants without schizophrenia) with and without hypertension (N=9,002 and N=33,705, respectively) or with and without a BMI >25 (N=16,983 and N=24,295, respectively). We adjusted all measures for age, gender, education, and ethnicity in all models. We included the vascular risk factor of interest (hypertension or elevated BMI) and the presence or absence of a schizophrenia diagnosis in the main effect model. The interaction between a schizophrenia diagnosis and the vascular risk factor was entered in a second step. We used Taylor linearization to adjust standard errors of means of estimates for complex survey sampling design effects including clustering data, and used the REGRESS procedure in the SUDAAN software package (4).

Hypertension, but not a BMI >25, had a significant negative impact on quality of life in patients with schizophrenia (Figure 1). We found no significant interaction between schizophrenia and a BMI >25 on quality of life.

FIGURE 1.

FIGURE 1. Health-Related Quality of Life for Patients With Schizophrenia and Comparison Subjects With and Without Hypertension and With and Without a Body Mass Index (BMI) Over 25

*p<0.001. **p<0.0001.

Friedman et al. (1) stress the importance of addressing individual cardiovascular risk factors in patients with schizophrenia. The dissociation between the effect of hypertension and a BMI >25 on quality of life in these patients is in line with this. Our findings stress the importance of screening for and treating hypertension in patients with schizophrenia, given its association with a poorer quality of life in this patient population.

Toronto, Ontario

Dr. Le Foll has received research grants from Pfizer and has performed consulting work for Richter Pharmaceuticals. The remaining authors report no financial relationships with commercial interests.

Accepted for publication in March 2011.

References

1. Friedman JI , Wallenstein S , Moshier E , Parrella M , White L , Bowler S , Gottlieb S , Harvey PD , McGinn TG , Flanagan L , Davis KL: The effects of hypertension and body mass index on cognition in schizophrenia. Am J Psychiatry 2010; 167:1232–1239LinkGoogle Scholar

2. Ranganath C , Minzenberg MJ , Ragland JD: The cognitive neuroscience of memory function and dysfunction in schizophrenia. Biol Psychiatry 2008; 64:18–25Crossref, MedlineGoogle Scholar

3. Narvaez JM , Twamley EW , McKibbin CL , Heaton RK , Patterson TL: Subjective and objective quality of life in schizophrenia. Schizophr Res 2008; 98:201–208Crossref, MedlineGoogle Scholar

4. Research Triangle Institute: Software for Survey Data Analysis (SUDAAN), version 9.0. Research Triangle Park, NC, Research Triangle Institute, 2004Google Scholar